Abstract
Janus kinase (JAK) inhibitors have been developed and are clinically available for management of active UC patients although most studies have been conducted for the outpatients and few studies have demonstrated its efficacy in endoscopic and histological remission of hospitalized patients with UC. The aim of the present study was to investigate the efficacy of upadacitinib, which is a novel selective JAK1 inhibitor, in the treatment of ulcerative colitis. We present the cases of three hospitalized patients with ulcerative colitis who achieved clinical remission after significant and rapid improvement with upadacitinib. While upadacitinib was used as the second-line treatment for patients with insufficient treatment effects for corticosteroids or ustekinumab, a patient received it just after admission because they were steroid dependent and previously used advanced therapy before hospitalization. All patients demonstrated rapid clinical responses within 7 days and the partial Mayo scores were 0 at week 8. All patients achieved confirmed endoscopic and histological remissions. We conclude that upadacitinib is a potential treatment option for hospitalized patients with an inadequate response to other biologics and JAK inhibitors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1–106.
Chaparro M, Czuber-Dochan W, Eder P, et al. ECCO Guidelines on therapeutics in ulcerative colitis: surgical treatment. J Crohns Colitis. 2022;16:179–89.
Naganuma M, Kobayashi T, Kunisaki R, et al. Real-world efficacy and safety of advanced therapies in hospitalized patients with ulcerative colitis. J Gastroenterol. 2023;58:1198–210.
Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099–105.
Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113–28.
Ghosh S, Sanchez Gonzalez Y, Zhou W, et al. Upadacitinib treatment improves symptoms of bowel urgency and abdominal pain, and correlates with quality of life improvements in patients with moderate to severe ulcerative colitis. J Crohns Colitis. 2021;15:2022–30.
Panés J. Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance. J Crohns Colitis. 2022;16:i373–4.
Loftus EV Jr, Colombel JF, Takeuchi K, et al. Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1. Gastroenterol Hepatol (NY). 2022;18:9.
Lasa JS, Olivera PA, Danese S, et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:161–70.
Gilmore R, Tan L, Fernandes R, et al. Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis. J Crohns Colitis. 2023. https://doi.org/10.1093/ecco-jcc/jjad115.
Berinstein JA, Karl T, Patel A, et al. Effectiveness of upadacitinib for patients with acute eevere ulcerative colitis: a multi-center experience. Am J Gastroenterol. 2024. https://doi.org/10.14309/ajg.0000000000002674.
Acknowledgements
We would also like to thank Editage (www.editage.jp) for English language editing.
Funding
There is no funding for presenting these case series.
Author information
Authors and Affiliations
Contributions
MN conceived the study. NN, YH, YS, YI, NF, and TF designed the main concept of this study. NN, TO and MN participated in clinical information acquisition. NN and MN drafted and wrote the manuscript. All authors contributed to critical review and approved the final draft.
Corresponding author
Ethics declarations
Conflict of interest
Makoto Naganuma received grants from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, Kyorin Pharmaceutical Co., Ltd., and lecture fees from Tanabe Pharma Corporation, AbbVie GK, Kyorin Pharmaceutical Co., Ltd. Kissei Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., JIMRO Co., Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., EA Pharma Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., and Mochida Pharmaceutical Co., Ltd., Corporation, AbbVie GK, outside the submitted work.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Nakamura, N., Honzawa, Y., Ohtsu, T. et al. Efficacy of upadacitinib in the achievement of clinical and endoscopic remission in hospitalized patients with ulcerative colitis. Clin J Gastroenterol (2024). https://doi.org/10.1007/s12328-024-01976-1
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12328-024-01976-1